Kiromic BioPharma, Inc. (KRBP) Prices 1.25M Share IPO at $12/Sh

Kiromic BioPharma, Inc. (NASDAQ: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology, today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $12.00 per share, for gross proceeds of $15,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments.

The shares are expected to begin trading on the Nasdaq Capital Market on October 16, 2020 under the ticker symbol “KRBP.” The offering is expected to close on October 20, 2020, subject to satisfaction of customary closing conditions.

ThinkEquity, a division of Fordham Financial Management, Inc. is acting as sole book-running manager for the offering. Paulson Investment Company, LLC is acting as co-manager for the offering.

You May Also Be Interested In

• Live Oak Acquisition Corp. VI prices $200M IPO on Nasdaq
• Vogenx adds consulting veteran Ken Toombs to its board
• Leader's Advantage Acquisition Corp. closes $150M IPO on Nasdaq